logous rescue following myeloablative therapy. 1 In this context, PBSC can be successfully mobilised with chemotherapy in combination with granulocyte colony-stimulatWe have carried out an analysis of 44 patients undergoing allogeneic PBSC transplants from fully HLAing factor (G-CSF) or with G-CSF alone. 2 Reports of the first allogeneic PBSC transplants (PBSCT) showed that matched related donors with particular emphasis on engraftment kinetics and the incidence and severity of PBSC could be safely mobilised from normal donors using G-CSF alone and could achieve trilineage engraftment in GVHD. The recipients had a median age of 37 years (range 5-56 years), 16 patients had standard-risk disthe recipients, without severe graft versus-host-disease (GVHD). 3, 4 The feasibility of this approach has recently ease and 28 had poor-risk disease. GVHD prophylaxis was with cyclosporin A and methotrexate (n = 41), been confirmed in several reported series of patients undergoing allogeneic PBSCT. [5] [6][7][8] In these reports large cyclosporin A alone (n = 2) or cyclosporin A and methylprednisolone (n = 1). Stem cells were mobilised using numbers of CD34 + cells were successfully collected from donors following administration of G-CSF and the data G-CSF, collecting a median of 5.75 × 10 6 CD34 + cells/kg recipient weight (range 0.94-35 × 10 6 CD34 + cells/kg). confirmed that blood stem cells resulted in long-term haemopoietic engraftment following transplantation. They Engraftment times to a neutrophil count Ͼ0.5 × 10 9 /l and platelets Ͼ20 × 10 9 /l were achieved at a median of also suggested that there may be advantages over allogeneic bone marrow transplantation (BMT) in terms of faster day +14 (range 10-25) and day + 14 (range 9-130) respectively. Patients receiving у4 × 10 6 CD34 + cells/kg haemopoietic engraftment, as is the case in autologous transplantation, 9 however, the number of CD34 + cells had significantly accelerated neutrophil and platelet engraftment and this number of CD34 + cells would required for optimal engraftment is still not certain. Allogeneic PBSCT have been performed in the United appear to be a prerequisite for maximum engraftment using PBSC. Acute GVHD occurred in 25 of 43 evaluKingdom (UK) since 1993. To obtain an overview of this activity we surveyed 20 BMT units in the UK and report an able patients although in only 12 was this clinically significant (grades II-IV). Chronic GVHD has occurred in analysis of 44 patients, from nine centres, where allogeneic transplantation using PBSC from related donors had been 17 out of 36 evaluable patients, there was no significant difference between the standard-and poor-risk groups undertaken between March 1993 and March 1996, specifically looking at engraftment kinetics and the incidence of in incidence of either acute or chronic GVHD. In conclusion, these results confirm the feasibility of using acute and chronic GVHD. PBSC for allogeneic transplantation without evidence for increased risk of either acute or chronic GVHD and provide further evidence supporting the potential of Patients and methods PBSC to replace bone marrow as the major source of haemopoietic cells for allogeneic transplantation.
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(range day +0-20), the median duration was for 6 days. MDS = myelodysplastic syndrome; PRV = polycythaemia rubra vera;
Statistics CML = chronic myeloid leukaemia; CP = chronic phase; AP = accelerated phase; SAA = severe aplastic anaemia.
Statistical analysis was done using Statistical Package for Social Scientists (SPSS, Chicago, IL, USA) and Statpak (Northwest Analytical, Portland, OR, USA). Engraftment vious BMT (four allogeneic and one autologous). These kinetics were analysed using a Mann-Whitney U test and patients undergoing a second transplant received PBSC GVHD data were analysed using Fisher's exact test. from the original donor.
Results

Donors
The stem cell donors were all fully HLA-matched family Engraftment members, 43 were siblings and one was a mother. Their median age was 39 years (range 18-63 years), 26 donors Overall engraftment of both neutrophils and platelets was prompt. As shown in Table 2 , engraftment to an absolute were male and 18 were female, with a donor-recipient sex mismatch in 25 cases. Ethical Committee approval was neutrophil count (ANC) of Ͼ0.5 × 10 9 /l was achieved at a median of day +14 (range 10-25 days) and platelets to obtained at individual centres and informed consent was obtained fom both donors and recipients. Ͼ20 × 10 9 /l was achieved at a median of day +14 (range 9-130). One patient had delayed platelet engraftment. At transplant this patient had half the PBSC infused (3 × 10 6 Mobilisation and collection of PBSC CD34 + cells/kg) and the other half was cryopreserved; at day +120 with a platelet count of 12 × 10 9 /l, the cryopre-PBSC were mobilised using subcutaneous G-CSF for 4-6 days (median 5 days), the majority of donors (n = 38) served stem cells were infused, with subsequent platelet engraftment to Ͼ50 × 10 9 /l achieved after a further 20 days. received G-CSF at a dose of 10 g/kg/day, and the other donors received G-CSF either at a dose of 5 g/kg/day (n We analysed the effect that the number of CD34 + cells infused had on the speed of engraftment. Using various cut-= 5) or 6.4 g/kg/day (n = 1). Donors subsequently underwent a median of two leucaphereses (range 1-3) with offs we found that patients who received у4 × 10 6 CD34 + cells/kg had particularly rapid engraftment. As shown in the first leucapheresis on the day following the 4th day of G-CSF. Both G-CSF administration and leucapheresis were Table 2 , those patients who received у4 × 10 6 CD34 + cells had significantly faster engraftment to an ANC Ͼ1.0 × 10 9 /l well tolerated and no adverse effects were reported. In 39 cases the donor PBSC were given immediately, however, (15 days compared with 19 days) and to platelets Ͼ20 × 10 9 /l (13 days compared with 20 days). Figure 1 in two cases the PBSC were cryopreserved between collection and infusion and in three cases the collection from shows scatter plots of the relationship between the number of CD34 + cells infused and engraftment times to an ANC the first leucapheresis was cryopreserved, then thawed and infused with fresh PBSC from subsequent leucaphereses.
Ͼ1.0 × 10 9 /l and platelets Ͼ20 × 10 9 /l. The median number of CD34
+ cells infused in the 31 patients receiving Donor PBSC were given on day 0 as a single infusion. None of the PBSC harvests underwent any form of T cell у4 × 10 6 cells/kg was 7.25 × 10 6 CD34 + cells/kg (range 4.05-35 × 10 6 ), compared with a median of 2.55 × 10 6 depletion or CD34 + positive selection. Leucapheresis pro- 
CD34
+ cells/kg (range 0.94-3.9 × 10 6 ) in the other 11 pawas clinically significant in 12 cases (grades II-IV). However, 31 out of 43 patients (72 %) did not develop or had tients who received Ͻ4 × 10 6 CD34 + cells/kg. Twenty patients received G-CSF post-transplant but this did not result only mild (grade 1) GVHD. When these data were analysed with respect to patient risk group, only three out of 16 evalin significantly more rapid neutrophil engraftment (P Ͻ 0.8 for engraftment to neutrophil counts Ͼ0.5 and 1.0 × 10 9 /l uable patients with good-risk disease developed significant acute GVHD, compared to nine out of 27 evaluable patients (data not shown)).
with advanced disease. However, these differences were not statistically significant. Chronic GVHD occurred in 17 out GVHD of 36 evaluable patients. There was no statistical difference in incidence between the standard-and poor-risk groups The incidence of GVHD is summarised in Table 3 . Acute GVHD occurred in 25 out of 43 evaluable patients, which although the extensive GVHD occured mainly in the poor- delayed. As yet no such clear threshold has been established for allogeneic PBSCT. In this study, the 11 patients who received Ͻ4 × 10 6 CD34 + cells/kg had significantly slower neutrophil and platelet engraftment compared to patients receiving у4 × 10 6 CD34 + cells/kg, suggesting that risk patients. The time period for evaluating chronic GVHD was 6 months from transplantation, thus the eight patients this figure may represent a target dose of CD34 + cells for rapid engraftment. The CD34
+ analysis was performed in not surviving this time were excluded from the analysis.
each institution and although the methodology used was consistent between laboratories, CD34 + analysis is known Outcome to be technically difficult with centre-to-centre variation. Despite these difficulties we found that patients receiving At the time of survey 21 patients had died, eight from relapsed disease, seven from GVHD (four acute and three Ͻ4 × 10 6 CD34 + cells/kg had significantly delayed neutrophil and platelet recovery. However, we believe that this chronic), five from sepsis or conditioning-related toxicity and one from an unrelated cause. The median follow-up finding would need to be confirmed by a single centre study given the limitations described above. Such a study may was 285 days (range 13-991 days). The longest diseasefree survival was 850 days, although this patient be difficult to undertake as most centres in the UK are now using a target dose of у4 × 10 6 CD34 + cells for patients subsequently died from relapsed disease. There are two patients who have relapsed and are still alive. Of the five undergoing allogeneic PBSCT. In this study, not all the patients who received CD34 + cells/kg engrafted rapidly (see patients who received their allogeneic PBSCT as a second transplant, of these, only one is alive (at day +343) Figure 1) ; this is perhaps not surprising as in the allogeneic setting, engraftment is affected by factors other than CD34 + and the other four have died; one from relapse at day +63, one from acute GVHD at day +16, one from chronic cell dose, including the use of post-transplant methotrexate, post-transplant toxicities such as veno-occlusive disease GVHD at day +226 and one from pneumonitis at day +201. The early transplant related mortality (Ͻ100 days) was and viral infections, including CMV. In this study there were 20 patients receiving G-CSF. However, the variation 18%.
in dose and date of starting made analysis of its effect on neutrophil engraftment impossible. The patients in this study were heterogeneous with Discussion respect to their underlying diagnosis and disease stage at the time of transplant, but fall into two major groups, ie Experience in using PBSC as an alternative to bone marrow for allogeneic transplantation continues to develop. Here, those transplanted with early disease and those with advanced leukaemia or lymphoma including five patients we present data confirming that their use is associated with rapid engraftment and with a low incidence of severe acute who had relapsed after a previous transplant. Despite these differences the vast majority of patients received identical GVHD; indeed, significant GVHD was mainly confined to patients with advanced disease at the time of transplant.
GVHD prophylaxis with cyclosporin A and a short course of methotrexate. Despite the fact that the patients in our Furthermore, within the limitation of a multicentre study we present evidence to suggest that the infusion of study had a median age of 37 years and that the majority had advanced disease, 72% had no or only grade 1 acute у4 × 10 6 CD34 + cells is associated with optimal engraftment kinetics.
GVHD. Thus, the overall risk of acute GVHD in this series is comparable to that reported for good-risk patients The donors in our series were all mobilised with G-CSF, the majority of donors (86%) received a dose of 10 undergoing allogeneic BMT using cyclosporin A and methotrexate for GVHD prophylaxis. 14, 15 Indeed in our g/kg/day for 4 days prior to the first leucapheresis. A median of 5.75 × 10 6 CD34 + cells/kg recipient weight experience patients with good risk disease have had a particularly low incidence of acute GVHD although the num-(range 0.94-35 × 10 6 CD34 + cells/kg) were collected with a median of two leucaphereses. There was no significant bers of patients remain small. Overall, our data suggests that standard GVHD prophylaxis regimens using cyclospodifference in CD34
+ cell yield with different doses of G- 
